Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19284778 | 0.85 | HCAR2 (0.59) | HCAR2LMNAAKR1B10AKR1B1CA12 | |
| SCHEMBL1531595 | 0.84 | CA12 (0.48) | HCAR2LMNACA12CA9ALDH1A1 | |
| SCHEMBL13529290 | 0.78 | HCAR2 (0.51) | HCAR2LMNAAKR1B10AKR1B1CA12 | |
| SCHEMBL9106935 | 0.78 | HCAR2 (0.51) | HCAR2LMNAAKR1B10AKR1B1CA12 | |
| SCHEMBL15751210 | 0.76 | HCAR2 (0.46) | HCAR2LMNAAKR1B10AKR1B1CA12 | |
| SCHEMBL9515999 | 0.75 | HCAR2 (0.65) | HCAR2LMNAAKR1B10AKR1B1CA12 | |
| SCHEMBL9395526 | 0.75 | HCAR2 (0.69) | HCAR2LMNAAKR1B10AKR1B1CA12 | |
| SCHEMBL337504 | 0.75 | HCAR2 (0.89) | HCAR2LMNAAKR1B10AKR1B1CA12 | |
| SCHEMBL357565 | 0.75 | HCAR2 (0.89) | HCAR2LMNAAKR1B10AKR1B1CA12 | |
| SCHEMBL337503 | 0.75 | HCAR2 (0.89) | HCAR2LMNAAKR1B10AKR1B1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212175-B2 | Pharmaceutical hypocholesterolemic compositions | LIPIDEON BIOTECHNOLOGY AG (CH) | 2015-12-15 | — | — | US | disclosed |
| US-9212175-B2 | Pharmaceutical hypocholesterolemic compositions | LIPIDEON BIOTECHNOLOGY AG (CH) | 2015-12-15 | — | — | US | disclosed |
| US-9018414-B2 | Substituted 3-phenylpropionic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-9018414-B2 | Substituted 3-phenylpropionic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-9018414-B2 | Substituted 3-phenylpropionic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| CN-102712577-B | Substituted 3-phenylpropionic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-15 | — | — | CN | disclosed |
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| CN-102712577-A | Substituted 3-phenylpropionic acids and the use thereof | BAYER SCHERING PHARMA AG | 2012-10-03 | — | — | CN | disclosed |
| US-20120065168-A1 | Pharmaceutical Hypocholesterolemic Compositions | LIPIDEON BIOTECHNOLOGY AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065168-A1 | Pharmaceutical Hypocholesterolemic Compositions | LIPIDEON BIOTECHNOLOGY AG (CH) | 2012-03-15 | — | — | US | disclosed |
| EP-2403848-A1 | PHARMACEUTICAL HYPOCHOLESTEROLEMIC COMPOSITIONS | Lipideon Biotechnology AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| WO-2011051165-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010100255-A1 | PHARMACEUTICAL HYPOCHOLESTEROLEMIC COMPOSITIONS | LIPIDEON BIOTECHNOLOGY AG (CH) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | FABP3, PC, PAH | HCAR2 71/4885LMNA 340/4885AKR1B10 1688/4885 |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | FABP3, PC, PAH | HCAR2 71/4885LMNA 340/4885AKR1B10 1688/4885 |
| US-20120065168-A1 | Pharmaceutical Hypocholesterolemic Compositions | CYP46A1, DHCR7, HMGCR | HCAR2 315/4885LMNA 1927/4885AKR1B10 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.